Clinical Trial Results:
A phase IIa, single-centre, randomised, placebo-controlled, double-blind, three-period crossover exploratory study investigating the effects on gut autonomic responses of single administrations of either 20mg or 200mg GW876008, a CRF1 antagonist, to adult patients with irritable bowel syndrome
Summary
|
|
EudraCT number |
2005-002976-14 |
Trial protocol |
GB |
Global completion date |
15 Oct 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 Nov 2016
|
First version publication date |
16 Nov 2016
|
Other versions |
|
Summary report(s) |
gsk-103143-synopsis-redact |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.